Declaration of interests SW has received payment or honoraria from AstraZeneca, Bausch Health Canada, Boehringer Ingelheim, Eli Lilly, Metsera, Neurogastrix, Novo Nordisk, and Regeneron for academic talks to colleagues; has been provided with medical writing support from AstraZeneca, Boehringer Ingelheim, Bausch Health Canada, Eli Lilly, and Novo Nordisk; and has an unpaid leadership role in The Obesity Society, and Obesity Canada. PF has received payment or honoraria from Amryt, Bial; Boehringer Ingelheim, FaesFarma, Janssen, Lilly, Merck, Novartis, NovoNordisk, Pronokal, and Sanofi, along with support to attend meetings from Bial, Medinfar, NovoNordisk, and Sanofi. JH has received payment or honoraria from Novo Nordisk, Eli Lilly, VIVUS, and AstraZeneca; and has received fees to participate on a data safety monitoring board or advisory board for Novo Nordisk, Eli Lilly, and VIVUS. MK is a full-time employee of, and holds shares in, Novo Nordisk; and is named on a US patent for semaglutide (“Semaglutide in Medical Therapy”, Patent Number: US 12,029,779 B2). KK is a full-time employee of, and holds shares in, Novo Nordisk. IL has received grants from Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk, Roche, and Pfizer, with all payments made to her institution; has received payment or honoraria from AbbVie, Altimmune, Alveus Therapeutics, Amgen, Antag Therapeutics, AstraZeneca, Bayer, Betagenon, Bioio, Biomea, Boehringer Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen/J&J, Juvena, Keros Therapeutic, Mediflix, Merck, Metsera, Neurocrine, Novo Nordisk, Pharmaventures, Pfizer, Regeneron, Roche, Sanofi, Shionogi, Source Bio, Structure Therapeutics, TARGET RWE, Terns Pharma, The Comm Group, Verdiva Bio, WebMD, and Zealand Pharma; and has received support to attend meetings from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Eli Lilly. MDLAQ-P is a full-time employee of Novo Nordisk and holds shares in Novo Nordisk, Eli Lilly, and Genmab. JR has received research grants from Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Carmot, Corcept, Eli Lilly, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Regeneron, Pfizer, Sanofi, Structure Therapeutics and Terns; and has served on scientific advisory boards and received honorarium or consulting fees from Amgen, Applied Therapeutics, Biomea Fusion, Eli Lilly, Hanmi, Novo Nordisk, Oramed, Regeneron, Regor, Roche, Sanofi, Structure Therapeutics, and Terns; and received honoraria for lectures from Eli Lilly, Novo Nordisk, and Sanofi. WTG has received grants as a principal investigator from Novo Nordisk, Eli Lilly & Co, Pfizer, Epitomee, Neurovalens, Zealand, Carmot/Roche, Terns Pharmaceuticals, Viking Therapeutics, and Pfizer, and for research from the UAB Diabetes Research Center (DK079626) funded by the US National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, with all payments made to his institution; has received consulting fees as an advisory board member from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, Fractyl Health, Alnylam Pharmaceuticals, Inogen, Zealand, Allurion, Carmot/Roche, Terns Pharmaceuticals, Neurocrine, KEROS Therapeutics, Gan & Lee, NodThera, and Regereron; has received fees to participate on a data safety monitoring board or advisory board for Boehringer Ingelheim and Eli Lilly; and is an unpaid member of the The Lancet Diabetes & Endocrinology Commission on definition and diagnostic criteria of clinical obesity, American Association of Clinical Endocrinology (AACE) update of obesity treatment algorithm, American Diabetes Association (ADA) nutrition recommendations update, and ADA Standards of Care for Obesity.
PubMed
GLP-1 Therapies